Development of novel ADCs: Conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling

Cancer Research

Volumn 74, Issue 20, 2014, Pages 5700-5710

  Cohen, Ruth ^a   Vugts, Danielle J ^a   Visser, Gerard W M ^a   Stigter Van Walsum, Marijke ^a   Bolijn, Marije ^a   Spiga, Marco ^b   Lazzari, Paolo ^b   Shankar, Ejith ^c   Sani, Monica ^b,d   Zanda, Matteo ^d,e   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KemoTech srl   (Italy)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d CNR   (Italy)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; IODINE N HYDROXYSUCCINIMIDE TUBULYSIN OH CONJUGATE I 131; IODINE N HYDROXYSUCCINIMIDE TUBULYSIN OMOM CONJUGATE I 131; IODINE TRASTUZUMAB I 124; IODINE TRASTUZUMAB TUBULYSIN OH CONJUGATE I 131; IODINE TRASTUZUMAB TUBULYSIN OMOM CONJUGATE I 131; IODINE TUBULYSIN OH I 101; IODINE TUBULYSIN OMOM I 101; IODINE TUBULYSIN OMOM I 101 ZIRCONIUM TRASTUZUMAB ZR 89 CONJUGATE; MONOCLONAL ANTIBODY; TETRAPEPTIDE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TUBULYSIN OH; TUBULYSIN OMOM; UNCLASSIFIED DRUG; ZIRCONIUM TRASTUZUMAB ZR 89; TUB-OH-TRASTUZUMAB; TUB-OMOM-TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CHROMATOGRAPHY; CONTROLLED STUDY; COVALENT BOND; DOSE RESPONSE; DRUG ANTIBODY RATIO; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MONITORING; DRUG PURITY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; RADIOIODINATION; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; DRUG STABILITY; NUDE MOUSE; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG STABILITY; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MICE, NUDE; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908102253     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1141     Document Type: Article

References (37)

1. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006;5:147-59.
2. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science 2013;341:1192-8.
3. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 2013;76:248-62.
4. Steinmetz H, Glaser N, Herdtweck E, Sasse F, Reichenbach H, Hoöfle G. Isolation, crystal and solution structure determination, and biosynthesis of tubulysins-powerful inhibitors of tubulin polymerization from myxobacteria. Angew Chem Int Ed Engl 2004;43:4888-92.
5. Patterson AW, Peltier HM, Sasse F, Ellman JA. Design, synthesis, and biological properties of highly potent tubulysin D analogues. Chem Eur J 2007;13:9534-41.
6. Shankar SP, Jagodzinska M, Malpezzi L, Lazzari P, Manca I, Greig IR, et al. Synthesis and structure-activity relationship studies of novel tubulysin U analogues-effect on cytotoxicity of structural variations in the tubuvaline fragment. Org Biomol Chem 2013;11:2273-87.
7. Schluep T, Gunawan P, Ma L, Jensen GS, Duringer J, Hinton S, et al. Polymeric tubulysin-peptide nanoparticles with potent antitumor activity. Clin Cancer Res 2009;15:181-9.
8. Zolot RS, Basu S, Million RP. Antibody-drug conjugates. Nat Rev Drug Discov 2013;12:259-60.
9. Sapra P, Shor B. Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Ther 2013;138:452-69.
10. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 2010;21:5-13.
11. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84.
12. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90.
13. Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009;69:2358-64.
14. Zhao RY, Wilhelm SD, Audette C, Jones G, Leece BA, Lazar AC, et al. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem 2011;54:3606-23.
15. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65.
16. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010;16:888-97.
17. 89Zr-labeled monoclonal antibodies. J Nucl Med 2003;44:1271-81.
18. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 2008;19:759-65.
19. Van Gog FB, Visser GW, Stroomer JW, Roos JC, Snow GB, Van Dongen GA. High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions. Cancer 1997;80:2360-70.
20. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, et al. Characterization of a novel cell line established from a patient with herceptin-resistant breast cancer. Mol Cancer Ther 2004;3:1585-92.
21. Cohen R, Vugts DJ, Stigter-Van Walsum M, Visser GW, Van Dongen GA. Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-mode fluorescence and PET imaging. Nat Protoc 2013;8:1010-8.
22. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77-89.
23. Tijink BM, Perk LR, Budde M, Stigter-van Walsum M, Visser GW, Kloet RW, et al. (124) I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131) I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging 2009;36:1235-44.
24. Visser GW, Klok RP, Klein-Gebbink JW, Ter Linde T, Van Dongen GA, Molthoff CF. Optimal quality Iodine-131-monoclonal antibodies upon high dose labeling in a large reaction volume and temporarily coating the antibody with iodogen. J Nucl Med 2001;42:509-19.
25. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-704.
26. Van Dongen GA, Visser GW, Vrouenraets MB. Photosensitizer immunoconjugates. Adv Drug Deliv Rev 2003;13:31-52.
27. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009;13:235-44.
28. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 2010;21:2153-63.
29. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Sitespecific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008;26:925-32
30. Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 2010;16:4769-78.
31. Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem 2011;22:1994-2004.
32. Verel I, Visser GW, Boerman OC, Van Eerd JE, Finn R, Boellaard R, et al. The long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Biopharm 2003;18:655-61.
33. Van Dongen GA, Vosjan MJ. Immuno-PET: shedding light on clinical antibody development. Cancer Biother Radiopharm 2010;25:375-85.
34. 89Zr-PET in the development and application of therapeutic monoclonal antibodies and other biologicals. Curr Top Med Chem 2013;14:446-57.
35. 89Zr-trastuzumab biodistribution and HER2 PET imaging in metastatic breast cancer patients. Clin Pharmacol Ther 2010;87:586-92.
36. Lazar AC, Wang L, Blaättler WA, Amphlett G, Lambert JM, Zhang W. Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. Rapid Commun Mass Spectrom 2005;19:1806-14.
37. Wang L, Amphlett G, Blaättler WA, Lambert JM, Zhang W. Structural characterization of the maytansonoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 2005;14:2436-46.